Researchers found data that showed the effectiveness of galcanezumab treatment was reduced during the posttreatment period, yet without a return to baseline, and there was still a significant reduction of monthly migraine days following treatment.
All articles by Erin Kelly
-
Latest News Your top articles for Saturday
For More Personalized News -
Haymarket Medical NetworkTop Picks
- Loading...
Continuing Medical Education (CME/CE) Courses